```

[Federal Register Volume 86, Number 29 (Tuesday, February 16, 2021)]
[Notices]
[Page 9521]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03016]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2021-1 Phase 
I: Pediatric Formulations of Select Second Line Drugs for Treating 
Tuberculosis (Topic 97).
    Date: February 22, 2021.
    Time: 11:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F58, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Mario Cerritelli, Ph.D., Scientific Review 
Officer, Scientific Review Program, National Institute of Allergy 
and Infectious Diseases, National Institutes of Health, 5601 Fishers 
Lane, Room 3F58, Rockville, MD 20892, 240-669-5199, 
[email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2021-1 Phase 
I: Pediatric Formulations of Select Second Line Drugs for Treating 
Tuberculosis (Topic 96).
    Date: February 24, 2021.
    Time: 11:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F58, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Mario Cerritelli, Ph.D., Scientific Review 
Officer, Scientific Review Program, National Institute of Allergy 
and Infectious Diseases, National Institutes of Health, 5601 Fishers 
Lane, Room 3F58, Rockville, MD 20892, 240-669-5199, 
[email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2021-1 Phase 
II: Pediatric Formulations of Select Second Line Drugs for Treating 
Tuberculosis (Topic 97).
    Date: February 24, 2021.
    Time: 4:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3F58, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Mario Cerritelli, Ph.D., Scientific Review 
Officer, Scientific Review Program, National Institute of Allergy 
and Infectious Diseases, National Institutes of Health, 5601 Fishers 
Lane, Room 3F58, Rockville, MD 20892, 240-669-5199, 
[email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: February 9, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-03016 Filed 2-12-21; 8:45 am]
BILLING CODE 4140-01-P
```